Migraine Research Team, Including Dr Sagar Munjal and Dr Alix Bennett of Promius Pharma, Honored at AHS 2017 With the Harold G. Wolff Lecture Award

Princeton, NJ, USA. June 9, 2017 – Promius Pharma LLC announced that 2 of its scientists, Sagar Munjal, MD, and Alix Bennett, PhD, along with a team of researchers including Richard B. Lipton, MD, Dawn C. Buse, PhD, Rami Burstein, PhD, Kristina Fanning, PhD, and Michael L. Reed, PhD, are being honored today by the American Headache Society (AHS) with the prestigious Harold G. Wolff Lecture Award at the AHS 59th Annual Scientific Meeting in Boston.

Dr Lipton was the lead author of the paper that was awarded the H. G. Wolff Lecture Award, along with co-authors Dr Munjal and Dr Bennett of Promius Pharma. The manuscript, titled “Allodynia Is Associated with Initial and Sustained Response to Acute Migraine Treatment: Results from the AMPP Study,” has been accepted for publication in *Headache.*

The H. G. Wolff Lecture Award is granted annually by the American Headache Society for the best paper on headache, head, or face pain and the nature of pain itself. It is made in tribute to Dr H. G. Wolff (1898-1962), an American neurologist, scientist, and a pioneer in the study of psychosomatic illness who has been called the father of modern headache research.

“We are proud of the outstanding work that Dr Munjal, Dr Bennett, and their colleagues have done on the AMPP Study, which advances our understanding of allodynia in migraine,” said Anil Namboodiripad, PhD, Senior Vice President, Proprietary Products and President, Promius Pharma. “Their award-winning research exemplifies the commitment that Promius has made to patients living with migraine.”

Sagar Munjal, MD, is Senior Director of Neurology Clinical Development & Medical Affairs at Promius Pharma. Alix Bennett, PhD, is Director of Medical Affairs at Promius Pharma. Richard B. Lipton, MD, is Director of Montefiore Headache Center and Vice Chair of Neurology, and the Edwin S. Lowe Chair in Neurology at Albert Einstein College of Medicine. Dawn C. Buse, PhD, is Director of Behavioral Medicine at Montefiore Headache Center and Associate Professor of Neurology at Albert Einstein College of Medicine. Rami Burstein, PhD, is Vice Chair of Research at Beth Israel Deaconess Medical Center in Boston, MA. Michael Reed, PhD, and Kristina Fanning, PhD, are the employees of Vedanta Research in Chapel Hill, NC.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency/ severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.
About the AMPP Study
Migraine impacts millions of people, and sustained pain relief may be difficult to achieve, even among those who respond initially to treatment. Sponsored by the National Headache Foundation, the AMPP Study provides cross-sectional and longitudinal (2004-2009) mailed questionnaire data from a large sample of persons with severe headache and migraine selected to be representative of the US population. Originally, 120,000 US households were surveyed; 24,000 adults with “severe headache” were followed annually from 2005-2009. The AMPP Study obtained sociodemographics, headache features, comorbid health conditions, and other information.

About Promius Pharma LLC
Promius Pharma is a wholly owned subsidiary of Dr. Reddy’s Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients’ needs in dermatology and neurology. For more information, visit www.promiuspharma.com.

Contact information:
Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
www.promiuspharma.com

Investor Relations:
Ashish Girotra (USA)
ashishg@drreddys.com
+1 (609) 375-6145

Media Relations:
Lori McCreary (USA)
lmccreary@drreddys.com
+1 (609) 375-2995

Copyright 2017 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.